150 Fayetteville Street
Vivelix Pharmaceuticals is an emerging specialty biopharmaceutical company focused on licensing, developing and commercializing gastroenterology and hepatology treatments.
Formed in March 2016, Vivelix is founded and staffed by an experienced team of gastroenterology drug developers and marketers, and funded by private equity investment.
The leadership team consists of eight former employees of Salix Pharmaceuticals, Inc. with more than 150 years of collective clinical, drug development, business development and commercialization experience, including over 75 years of experience in gastroenterology and hepatology. This same management team held direct responsibility for successfully licensing, developing, and commercializing numerous leading and transformative products for the gastroenterology and hepatology community, their patients and caregivers.
Founder & CEO: William P. Forbes, Pharm. D.
Founder & Chief Development Officer: Enoch B. Bortey, Ph.D.
Founder & CMO: Craig A. Paterson, M.D., M.Sc., MBA
Founder & Chief Marketing Officer: Daniel P. Lundberg
Founder & Vice President: Pamela L. Golden, Ph.D.
Founder & Director, Outsourcing, Financial & Project Management: Jill Aremia
Founder & Executive Director, CMC Operations: Christopher A. Martin, M.S.
Executive Director, Strategic Planning & Business Development: Corey M. Hansen, MBA